News | February 07, 2025
Akums reports Q3 FY25 adjusted PAT at Rs. 66.3 Cr
Branded formulation business continues to perform well across domestic and export markets
Branded formulation business continues to perform well across domestic and export markets
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
EBITDA margins expand to 31.3%
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
The site’s GMP Certification has been successfully renewed
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024
Increases speed to market for drug developers working on nucleic acid therapeutics
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
The company will receive GMP compliance certificate which will further help to accelerate the business growth across the globe
The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL
Subscribe To Our Newsletter & Stay Updated
